Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021
   Pooled it
2. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2020
   Pooled it
3. Convalescent plasma therapy for COVID-19 in patients with nasal catheter oxygen therapy.Journal of thoracic disease · 2025
   Article
4. Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates.Viruses · 2023
   Article
5. Thrombocytopenia and clinical outcomes among patients with COVID-19 disease: A cohort study.Health science reports · 2023
   Article
6. Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
   Article
7. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study.Hematological oncology · 2022
   Article
8. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
   Review
9. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.Clinical lymphoma, myeloma & leukemia · 2021
   Article
10. Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders.Clinical hematology international · 2021
    Review
11. Efficacy of convalescent plasma therapy in severe COVID-19 patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021
    Article
12. People with blood disorders can be more vulnerable during COVID-19 pandemic: A hypothesis paper.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021
    Review
13. Convalescent plasma as a treatment modality for Coronavirus Disease 2019 in Indonesia: A case reports.Annals of medicine and surgery (2012) · 2021
    Article
14. A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.Iranian journal of medical sciences · 2021
    Review
15. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.Communications biology · 2021
    Article
16. Clinical trial protocols of repurposed prophylaxis for COVID-19: A review.Infectious diseases now · 2021
    Review
17. Knowledge and Attitudes of Young Adults Towards Donation of COVID-19 Convalescent Plasma and Its Therapeutic Properties.Journal of blood medicine · 2021
    Article
18. COVID-19 susceptibility variants associate with blood clots, thrombophlebitis and circulatory diseases.PloS one · 2021
    Article
19. The successful management of an elderly Covid-19 infected patient by plasmapheresis.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020
    Article
20. Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as